Serum sclerostin and glucose homeostasis : No association in healthy men. Cross-sectional and prospective data from the EGIR-RISC study
(2021) In Bone 143.- Abstract
Introduction: Sclerostin, an inhibitor of bone formation, has emerged as a potential negative regulator of glucose homeostasis. We aimed to investigate if serum sclerostin associates with insulin sensitivity, beta cell function, prediabetes or metabolic syndrome in healthy men. Materials and methods: Serum sclerostin was measured in basal and insulin-stimulated samples from 526 men without diabetes from the RISC cohort study. An OGTT was performed at baseline and after 3 years. An IVGTT and a hyperinsulinaemic-euglycaemic clamp were performed at baseline. Insulin sensitivity was estimated by the oral glucose sensitivity index (OGIS) and the M-value relative to insulin levels. Beta cell function was assessed by the acute and total... (More)
Introduction: Sclerostin, an inhibitor of bone formation, has emerged as a potential negative regulator of glucose homeostasis. We aimed to investigate if serum sclerostin associates with insulin sensitivity, beta cell function, prediabetes or metabolic syndrome in healthy men. Materials and methods: Serum sclerostin was measured in basal and insulin-stimulated samples from 526 men without diabetes from the RISC cohort study. An OGTT was performed at baseline and after 3 years. An IVGTT and a hyperinsulinaemic-euglycaemic clamp were performed at baseline. Insulin sensitivity was estimated by the oral glucose sensitivity index (OGIS) and the M-value relative to insulin levels. Beta cell function was assessed by the acute and total insulin secretion (ISRtot) and by beta cell glucose sensitivity. Results: Serum sclerostin levels correlated positively with age but were similar in individuals with (n = 69) and without (n = 457) prediabetes or the metabolic syndrome. Serum sclerostin was associated with measures of neither insulin sensitivity nor beta cell function at baseline in age-adjusted analyses including all participants. However, baseline serum sclerostin correlated inversely with OGIS at follow-up in men without prediabetes (B: −0.29 (−0.57, −0.01) p = 0.045), and inversely with beta cell glucose sensitivity in men with prediabetes (B: −13.3 (−26.3, −0.2) p = 0.046). Associations between serum sclerostin and 3-year changes in measures of glucose homeostasis were not observed. Acute hyperinsulinemia suppressed serum sclerostin (p = 0.02), and this reduction correlated with OGIS and ISRtot. Conclusions: Overall, serum sclerostin was not associated with prediabetes, insulin sensitivity or insulin secretion in healthy men. The inverse relationship between serum sclerostin and insulin sensitivity at follow-up was weak and likely not of clinical relevance. The ability of insulin to reduce sclerostin, possibly promoting bone formation, needs to be clarified.
(Less)
- author
- Lauterlein, Jens Jacob L. ; Hermann, Pernille ; Konrad, Thomas ; Wolf, Peter ; Nilsson, Peter LU ; Sánchez, Rafael Gabriel ; Ferrannini, Ele ; Balkau, Beverley ; Højlund, Kurt and Frost, Morten
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Bone-glucose interactions, Insulin secretion, Insulin sensitivity, Prediabetes, Sclerostin, Wnt/β-catenin/LRP5
- in
- Bone
- volume
- 143
- article number
- 115681
- publisher
- Elsevier
- external identifiers
-
- pmid:33035729
- scopus:85095415938
- ISSN
- 8756-3282
- DOI
- 10.1016/j.bone.2020.115681
- language
- English
- LU publication?
- yes
- id
- f1be5bc1-68ae-437e-bff0-985f2cd133fa
- date added to LUP
- 2020-11-13 07:09:53
- date last changed
- 2024-05-29 23:02:40
@article{f1be5bc1-68ae-437e-bff0-985f2cd133fa,
abstract = {{<p>Introduction: Sclerostin, an inhibitor of bone formation, has emerged as a potential negative regulator of glucose homeostasis. We aimed to investigate if serum sclerostin associates with insulin sensitivity, beta cell function, prediabetes or metabolic syndrome in healthy men. Materials and methods: Serum sclerostin was measured in basal and insulin-stimulated samples from 526 men without diabetes from the RISC cohort study. An OGTT was performed at baseline and after 3 years. An IVGTT and a hyperinsulinaemic-euglycaemic clamp were performed at baseline. Insulin sensitivity was estimated by the oral glucose sensitivity index (OGIS) and the M-value relative to insulin levels. Beta cell function was assessed by the acute and total insulin secretion (ISR<sub>tot</sub>) and by beta cell glucose sensitivity. Results: Serum sclerostin levels correlated positively with age but were similar in individuals with (n = 69) and without (n = 457) prediabetes or the metabolic syndrome. Serum sclerostin was associated with measures of neither insulin sensitivity nor beta cell function at baseline in age-adjusted analyses including all participants. However, baseline serum sclerostin correlated inversely with OGIS at follow-up in men without prediabetes (B: −0.29 (−0.57, −0.01) p = 0.045), and inversely with beta cell glucose sensitivity in men with prediabetes (B: −13.3 (−26.3, −0.2) p = 0.046). Associations between serum sclerostin and 3-year changes in measures of glucose homeostasis were not observed. Acute hyperinsulinemia suppressed serum sclerostin (p = 0.02), and this reduction correlated with OGIS and ISR<sub>tot</sub>. Conclusions: Overall, serum sclerostin was not associated with prediabetes, insulin sensitivity or insulin secretion in healthy men. The inverse relationship between serum sclerostin and insulin sensitivity at follow-up was weak and likely not of clinical relevance. The ability of insulin to reduce sclerostin, possibly promoting bone formation, needs to be clarified.</p>}},
author = {{Lauterlein, Jens Jacob L. and Hermann, Pernille and Konrad, Thomas and Wolf, Peter and Nilsson, Peter and Sánchez, Rafael Gabriel and Ferrannini, Ele and Balkau, Beverley and Højlund, Kurt and Frost, Morten}},
issn = {{8756-3282}},
keywords = {{Bone-glucose interactions; Insulin secretion; Insulin sensitivity; Prediabetes; Sclerostin; Wnt/β-catenin/LRP5}},
language = {{eng}},
publisher = {{Elsevier}},
series = {{Bone}},
title = {{Serum sclerostin and glucose homeostasis : No association in healthy men. Cross-sectional and prospective data from the EGIR-RISC study}},
url = {{http://dx.doi.org/10.1016/j.bone.2020.115681}},
doi = {{10.1016/j.bone.2020.115681}},
volume = {{143}},
year = {{2021}},
}